Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines
Irene Litvan, Jennifer G Goldman, Alexander I Tröster, Ben A Schmand, Daniel Weintraub, Ronald C Petersen, Brit Mollenhauer, Charles H Adler, Karen Marder, Caroline H Williams-Gray, Dag Aarsland, Jaime Kulisevsky, Maria C Rodriguez-Oroz, David J Burn, Roger A Barker, Murat Emre, Irene Litvan, Jennifer G Goldman, Alexander I Tröster, Ben A Schmand, Daniel Weintraub, Ronald C Petersen, Brit Mollenhauer, Charles H Adler, Karen Marder, Caroline H Williams-Gray, Dag Aarsland, Jaime Kulisevsky, Maria C Rodriguez-Oroz, David J Burn, Roger A Barker, Murat Emre
Abstract
Mild cognitive impairment is common in nondemented Parkinson's disease (PD) patients and may be a harbinger of dementia. In view of its importance, the Movement Disorder Society commissioned a task force to delineate diagnostic criteria for mild cognitive impairment in PD. The proposed diagnostic criteria are based on a literature review and expert consensus. This article provides guidelines to characterize the clinical syndrome and methods for its diagnosis. The criteria will require validation, and possibly refinement, as additional research improves our understanding of the epidemiology, presentation, neurobiology, assessment, and long-term course of this clinical syndrome. These diagnostic criteria will support future research efforts to identify at the earliest stage those PD patients at increased risk of progressive cognitive decline and dementia who may benefit from clinical interventions at a predementia stage.
Conflict of interest statement
Relevant conflicts of interest/financial disclosures: A.I.T. has held consultancies with Medtronic, St. Jude Medical, and Boston Scientific, has served on the advisory board of St. Jude Medical, has received honoraria from Medtronic and the Parkinson’s Disease Foundation, and has been awarded grants from Medtronic, GlaxoSmithKline, and the National Parkinson Foundation; D.W. has served on the advisory board of Teva Pharmaceuticals and has received honoraria from The Michael J. Fox Foundation for Parkinson’s Research; R.P. has held consultancies with GE Healthcare and Elan Pharmaceuticals, has served on the advisory boards of Pfizer and Janssen Alzheimer Immunotherapy, has been awarded grants from the National Institutes of Health (P50 AG016574 and U01 AG006786), and has received royalties from Oxford University Press; C.H.A. has held consultancies with Merck Serono and Teva Pharmaceuticals; K.M. has been awarded grants from the National Institutes of Health (NS36630 and RR024156); D.B. has received honoraria from Merck Serono and The Michael J. Fox Foundation for Parkinson’s Research and has received royalties from Henry Stewart Talks; R.B. has held consultancies with Oxford Biomedica, has served on the advisory board of Teva Lundbeck, has received honoraria from GlaxoSmithKline, has been awarded grants from Parkinson’s UK, the European Union FP7 program, the Child Health and Development Institute, and The Michael J. Fox Foundation for Parkinson’s Research, has been employed by the University of Cambridge, has received royalties from Wiley and Cambridge University Press, and has received monetary compensation from Springer for editorial work for the Journal of Neurology; and M.E. has held a consultancy with Merck Serono, has served on the advisory board of Merck Serono, has received honoraria from Merck Serono, and has received a clinical study grant from Teva Lundbeck.
Copyright © 2012 Movement Disorder Society.
Source: PubMed